{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:21:01Z","timestamp":1786119661595,"version":"build-2736575974"},"reference-count":11,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013,12]]},"DOI":"10.1097\/cmr.0000000000000014","type":"journal-article","created":{"date-parts":[[2013,8,22]],"date-time":"2013-08-22T10:48:39Z","timestamp":1377168519000},"page":"468-473","source":"Crossref","is-referenced-by-count":17,"title":["Everolimus in combination with paclitaxel and carboplatin in patients with metastatic melanoma"],"prefix":"10.1097","volume":"23","author":[{"given":"Ralph J.","family":"Hauke","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey R.","family":"Infante","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark S.","family":"Rubin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kent C.","family":"Shih","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward R.","family":"Arrowsmith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John D.","family":"Hainsworth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R5-7-20210129","doi-asserted-by":"crossref","first-page":"2478","DOI":"10.1002\/1097-0142(19900601)65:11<2478::AID-CNCR2820651114>3.0.CO;2-S","article-title":"A phase II trial of taxol in metastatic melanoma.","volume":"65","author":"Legha","year":"1990","journal-title":"Cancer"},{"key":"R9-7-20210129","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1097\/00000421-200206000-00016","article-title":"Phase II study of paclitaxel and carboplatin for malignant melanoma.","volume":"25","author":"Hodi","year":"2002","journal-title":"Am J Clin Oncol"},{"key":"R20-7-20210129","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1038\/sj.leu.2404471","article-title":"Antiproliferative activity of RAD001 (everolimus) as a single agent and combined with other agents in mantle cell lymphoma.","volume":"21","author":"Haritunians","year":"2007","journal-title":"Leukemia"},{"key":"R24-7-20210129","doi-asserted-by":"crossref","first-page":"29","DOI":"10.2307\/2530286","article-title":"A confidence interval for the median survival time.","volume":"38","author":"Brookmeyer","year":"1982","journal-title":"Biometrics"},{"key":"R25-7-20210129","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","article-title":"Nonparametric estimation from incomplete observations.","volume":"53","author":"Kaplan","year":"1958","journal-title":"J Am Stat Assoc"},{"key":"R26-7-20210129","doi-asserted-by":"crossref","first-page":"331S","DOI":"10.1158\/1078-0432.CCR-031212","article-title":"Cross-talk between estrogen receptor and growth factor pathways as a molecular target for overcoming endocrine resistance.","volume":"10","author":"Schiff","year":"2004","journal-title":"Clin Cancer Res"},{"key":"R30-7-20210129","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1073\/pnas.0510857103","article-title":"Cancer-specific mutations in PIK3CA are oncogenic in vivo.","volume":"103","author":"Bader","year":"2006","journal-title":"Proc Natl Acad Sci USA"},{"key":"R31-7-20210129","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1016\/S0190-9622(03)02473-3","article-title":"PTEN expression in normal skin, acquired melanocytic nevi, and cutaneous melanoma.","volume":"49","author":"Tsao","year":"2003","journal-title":"J Am Acad Dermatol"},{"key":"R32-7-20210129","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1002\/ijc.10294","article-title":"Nuclear PTEN expression and clinicopathologic features in a population-based series of primary cutaneous melanoma.","volume":"99","author":"Whiteman","year":"2002","journal-title":"Int J Cancer"},{"key":"R33-7-20210129","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1111\/j.1600-0560.2006.00592.x","article-title":"Phosphoinositide 3-kinase is not overexpressed in melanocytic lesions.","volume":"34","author":"Singh","year":"2007","journal-title":"J Cutan Pathol"},{"key":"R35-7-20210129","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1038\/sj.jid.5700026","article-title":"Examination of mutations in BRAF, NRAS, and PTEN in primary cutaneous melanoma.","volume":"126","author":"Goel","year":"2006","journal-title":"J Invest Dermatol"}],"container-title":["Melanoma Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/00008390-201312000-00007","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T18:52:00Z","timestamp":1786042320000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00008390-201312000-00007"}},"subtitle":["a phase II trial of the Sarah Cannon Research Institute Oncology Research Consortium"],"short-title":[],"issued":{"date-parts":[[2013,12]]},"references-count":11,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2013]]}},"URL":"https:\/\/doi.org\/10.1097\/cmr.0000000000000014","relation":{},"ISSN":["0960-8931"],"issn-type":[{"value":"0960-8931","type":"print"}],"subject":[],"published":{"date-parts":[[2013,12]]}}}